1. Home
  2. BME vs FLGT Comparison

BME vs FLGT Comparison

Compare BME & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BME
  • FLGT
  • Stock Information
  • Founded
  • BME 2005
  • FLGT 2011
  • Country
  • BME United States
  • FLGT United States
  • Employees
  • BME N/A
  • FLGT N/A
  • Industry
  • BME Trusts Except Educational Religious and Charitable
  • FLGT Medical Specialities
  • Sector
  • BME Finance
  • FLGT Health Care
  • Exchange
  • BME Nasdaq
  • FLGT Nasdaq
  • Market Cap
  • BME N/A
  • FLGT 508.7M
  • IPO Year
  • BME N/A
  • FLGT 2016
  • Fundamental
  • Price
  • BME $38.41
  • FLGT $17.62
  • Analyst Decision
  • BME
  • FLGT Hold
  • Analyst Count
  • BME 0
  • FLGT 1
  • Target Price
  • BME N/A
  • FLGT $16.00
  • AVG Volume (30 Days)
  • BME 34.0K
  • FLGT 727.9K
  • Earning Date
  • BME 01-01-0001
  • FLGT 05-02-2025
  • Dividend Yield
  • BME 6.26%
  • FLGT N/A
  • EPS Growth
  • BME N/A
  • FLGT N/A
  • EPS
  • BME 1.44
  • FLGT N/A
  • Revenue
  • BME N/A
  • FLGT $283,470,000.00
  • Revenue This Year
  • BME N/A
  • FLGT $11.70
  • Revenue Next Year
  • BME N/A
  • FLGT $9.90
  • P/E Ratio
  • BME $28.37
  • FLGT N/A
  • Revenue Growth
  • BME N/A
  • FLGT N/A
  • 52 Week Low
  • BME $35.53
  • FLGT $14.57
  • 52 Week High
  • BME $43.20
  • FLGT $25.11
  • Technical
  • Relative Strength Index (RSI)
  • BME 36.39
  • FLGT 57.62
  • Support Level
  • BME $38.20
  • FLGT $16.51
  • Resistance Level
  • BME $38.88
  • FLGT $17.20
  • Average True Range (ATR)
  • BME 0.42
  • FLGT 0.56
  • MACD
  • BME -0.01
  • FLGT 0.04
  • Stochastic Oscillator
  • BME 29.66
  • FLGT 98.23

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Share on Social Networks: